D Tc 99m Dimercaptosuccinic Acid SPECT Versus Planar

Dimercaptosuccinic Acid SPECT and Planar Clinical Trial

Official title:

Added Value of Tc99m Dimercaptosuccinic Acid SPECT Versus Planar Imaging in Detection of Renal Cortical Defects

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04091685
• Other study ID #: DSVP
• Status: Not yet recruiting
• Start date: September 2019
• Est. completion date: October 2020

Study information

• Verified date: September 2019
• Source: Assiut University
• Contact: Marwa Sayed Mahamed
• Phone: 00201010573518
• Email: marwasayed1599[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Knowing what will DMSA spect add to the DMSA planar in detection in renal cortical defects

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: October 2020
• Est. primary completion date: September 2020
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• patient with history of peylo nephritis.

Exclusion Criteria:

• pregnant women

Related Conditions & MeSH terms

• Dimercaptosuccinic Acid SPECT and Planar

Intervention

Device:
• Gamma camera imaging
Use gamma camera in detection of renal cortical defects

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison between DMSA spect and planar imaging	Analysis of DMSA spect and planar imaging to clarify early renal cortical defects	Baseline
Secondary	Clarify added value of DMSA spect over planar	Know if DMSA spect is necessary?	Baseline